Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer

Yan Gao; Yan Gao; Yulai Zhou; Yulai Zhou; Le Wei; Le Wei; Ziyang Feng; Ziyang Feng; Yihong Chen; Yihong Chen; Ping Liu; Ping Liu; Yinghui Peng; Yinghui Peng; Qiaoqiao Huang; Qiaoqiao Huang; Le Gao; Le Gao; Yongting Liu; Yongting Liu; Ying Han; Ying Han; Hong Shen; Hong Shen; Hong Shen; Changjing Cai; Changjing Cai; Shan Zeng; Shan Zeng; Shan Zeng

doi:10.3389/fimmu.2022.927811

Frontiers in Immunology (Jul 2022)

Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer

Yan Gao,
Yan Gao,
Yulai Zhou,
Yulai Zhou,
Le Wei,
Le Wei,
Ziyang Feng,
Ziyang Feng,
Yihong Chen,
Yihong Chen,
Ping Liu,
Ping Liu,
Yinghui Peng,
Yinghui Peng,
Qiaoqiao Huang,
Qiaoqiao Huang,
Le Gao,
Le Gao,
Yongting Liu,
Yongting Liu,
Ying Han,
Ying Han,
Hong Shen,
Hong Shen,
Hong Shen,
Changjing Cai,
Changjing Cai,
Shan Zeng,
Shan Zeng,
Shan Zeng

Affiliations

Yan Gao: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Yan Gao: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Yulai Zhou: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Yulai Zhou: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Le Wei: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Le Wei: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Ziyang Feng: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Ziyang Feng: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Yihong Chen: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Yihong Chen: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Ping Liu: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Ping Liu: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Yinghui Peng: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Yinghui Peng: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Qiaoqiao Huang: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Qiaoqiao Huang: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Le Gao: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Le Gao: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Yongting Liu: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Yongting Liu: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Ying Han: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Ying Han: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Hong Shen: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Hong Shen: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Hong Shen: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Changjing Cai: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Changjing Cai: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Shan Zeng: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Shan Zeng: Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China
Shan Zeng: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

DOI: https://doi.org/10.3389/fimmu.2022.927811
Journal volume & issue: Vol. 13

Abstract

Read online

Circular RNA (circRNA), a novel class of non-coding RNA, has been reported in various diseases, especially in tumors. However, the key signatures of circRNA-competitive endogenous RNA (ceRNA) network are largely unclear in colorectal cancer (CRC). We first characterized circRNAs profile by using circRNA-seq analysis from real-word dataset. The expression level of hsa_circ_0066351 in CRC tissues and cell lines was detected by quantitative real-time PCR. Then, cell proliferation assay was used to confirm the proliferation function of hsa_circ_0066351. Next, Cytoscape was used to construct circRNA–miRNA–mRNA networks. Last but not least, the landscape of hsa_circ_0066351–miRNA–mRNA in CRC had been investigated in the bulk tissue RNA-Seq level and single-cell Seq level. We proved that hsa_circ_0066351 was significantly downregulated in CRC cell lines and tissues (P < 0.001), and was negatively associated with distant metastasis (P < 0.01). Significantly, the expression of hsa_circ_0066351 was associated with better survival in patients with CRC. Function assays showed that hsa_circ_0066351 could inhibit CRC cells proliferation. In addition, a ceRNA network, including hsa_circ_0066351, two miRNAs, and ten mRNAs, was constructed. Our analyses showed that these ten mRNAs were consistently downregulated in pan-cancer and enriched in tumor suppressive function. A risk score model constructed by these ten downstream genes also indicated that they were related to the prognosis and immune response in CRC. In conclusion, we demonstrated that a novel circRNA (hsa_circ_0066351) inhibited CRC proliferation, and revealed a potential prognostic and immunotherapeutic biomarker in CRC.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords